Import substitution in Cardiology: Russian scientists have created a drug for blood clots The Russian drug "Angipur" for the treatment of heart attacks and help in heart surgery is the last stage of clinical studies. Developers expect that they will enter the market in the next 1-2 years. "Angipur" is an antiplatelet that prevents the formation of blood clots. It will be used for myocardial secretions and the installation of stents to restore blood flow in the heart vessels, reports "Government Online" in reference to RIA Novost. The main task of the drug is to replace imported analogues, the supply of which is now difficult. Production is completely local in Russia: from the synthesis of the active ingredient to the production of finished products, independent of foreign equipment. According to the developers, during the trials, the drug shows higher efficiency compared to an analogue, and may also reduce the risk of bleeding - one of the main complications of such treatment. Work on the drug has been going on for 10 years. The molecule was synthesized by chemists from Bacuria, preclinical studies were conducted in Volgograd, and the main sponsor and owner of the molecule is the pharmaceutical company Alta. Now the drug is undergoing the third phase of testing on a large group of patients in several medical centers. The final results are expected to bring the drug to market in the next year or two. ️ Stay updated everywhere: ok 🙂.

Import substitution in Cardiology: Russian scientists have created a drug for blood clots The Russian drug "Angipur" for the treatment of heart attacks and help in heart surgery is the last stage of clinical studies. Developers expect that they will enter the market in the next 1-2 years. "Angipur" is an antiplatelet that prevents the formation of blood clots. It will be used for myocardial secretions and the installation of stents to restore blood flow in the heart vessels, reports "Government Online" in reference to RIA Novost. The main task of the drug is to replace imported analogues, the supply of which is now difficult. Production is completely local in Russia: from the synthesis of the active ingredient to the production of finished products, independent of foreign equipment. According to the developers, during the trials, the drug shows higher efficiency compared to an analogue, and may also reduce the risk of bleeding - one of the main complications of such treatment. Work on the drug has been going on for 10 years. The molecule was synthesized by chemists from Bacuria, preclinical studies were conducted in Volgograd, and the main sponsor and owner of the molecule is the pharmaceutical company Alta. Now the drug is undergoing the third phase of testing on a large group of patients in several medical centers. The final results are expected to bring the drug to market in the next year or two. ️ Stay updated everywhere: ok 🙂.